Chapter 66
Erythema Multiforme, Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis
Benjamin S. Daniel,
Lizbeth Ruth Wheeler,
Dédée F. Murrell,
Benjamin S. Daniel
Department of Dermatology, St George Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorLizbeth Ruth Wheeler
Department of Dermatology, St George Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorDédée F. Murrell
Department of Dermatology, St George Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorBenjamin S. Daniel,
Lizbeth Ruth Wheeler,
Dédée F. Murrell,
Benjamin S. Daniel
Department of Dermatology, St George Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorLizbeth Ruth Wheeler
Department of Dermatology, St George Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorDédée F. Murrell
Department of Dermatology, St George Hospital and University of New South Wales, Sydney, Australia
Search for more papers by this authorBook Editor(s):Peter Hoeger,
Veronica Kinsler,
Albert Yan,
John Harper,
Arnold Oranje,
Christine Bodemer,
Margarita Larralde,
David Luk, Vibhu Mendiratta,
Diana Purvis,
Peter Hoeger
Search for more papers by this authorVeronica Kinsler
Search for more papers by this authorAlbert Yan
Search for more papers by this authorJohn Harper
Search for more papers by this authorArnold Oranje
Search for more papers by this authorChristine Bodemer
Search for more papers by this authorMargarita Larralde
Search for more papers by this authorVibhu Mendiratta
Search for more papers by this authorDiana Purvis
Search for more papers by this authorSummary
Erythema multiforme (EM), Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are a group of mucocutaneous diseases characterized by varying degrees of skin and mucosal involvement, with the latter two conditions associated with high morbidity and mortality. EM is typically caused by infections, especially herpes simplex virus. Patients present with target lesions with or without mucosal involvement. This is a self-limiting disease. SJS and TEN are characterized by cutaneous desquamation and mucosal involvement. They have a higher morbidity than EM. Medications and infections are the most common causes of SJS/TEN.
References
- Von Hebra F. Atlas der Hautkrankheiten. Vienna: Kaiserliche Akademie der Wissenchafte, 1866.
- Roujeau JC. What is going on in erythema multiforme? Dermatology 1994; 188: 249–50.
- Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child 1922; 24: 526–33.
- Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355–61.
- Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol 1990; 122: 837–46.
- Roujeau JC. Stevens–Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726–9.
- Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019–24.
- Bastuji-Garin S, Rzany B, Stern SR et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92–6.
- Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens–Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6–11.
- Wolf R, Wolf D, Davidovici B. In the pursuit of classifying severe cutaneous adverse reactions. Clin Dermatol 2007; 25: 348–9.
- Léauté-Labrèze C, Lamireau T, Chawki D et al. Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome. Arch Dis Child 2000; 83: 347–52.
- Huff JC, Weston WL, Tonnesen MG et al. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8: 763–75.
- Letko E, Papaliodis DN, Papaliodis GN et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of literature. Ann Allergy Asthma Immunol 2005; 94: 419–36.
- Borchers AT, Lee JL, Naguwa SM et al. Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598–605.
- Hsu DY, Brieva J, Silverberg N. et al. Pediatric Stevens Johnson Syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017; 76: 811–17.
- Dibek Misirlioglu E, Guvenir H, Bahceci S et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract 2017; 5(3): 757–63.
- Lonjou C, Thomas L, Borot N et al. A marker for Stevens–Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265–8.
- Tan JC, Murrell DF, Hersch MI. Genetic screening for human leukocyte antigen alleles prior to carbamazepine treatment. J Clin Neurosci 2015; 22(12): 1992–3.
- Ferrell PB Jr, McLeod HL. Carbamazepine, HLA–B*1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543–6.
- Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25–32.
- Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genom 2008; 18: 99–107.
- Mirakian R, Ewan PW, Durham SR et al. BSACI guidelines for the management of drug allergy. Clin Exp Dermatol 2009; 39: 43–61.
- Dore J, Salisbury RE. Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. J Burn Care Res 2007; 28: 865–70.
- Levi N, Bastuji-Garin S, Mockenhaupt M et al. Medications as risk factors of Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123: e297–e304.
- Caproni M, Torchia D, Volpi W et al. Expression of matrix metalloproteinases 2, 9, 11 in erythema multiforme: immunohistochemical comparison with Stevens–Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2008; 158: 1163–6.
- Quaglino P, Caproni M, Antiga E et al. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens–Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. Dermatology 2007; 214: 296–304.
- Siedner-Weintraub Y, Gross I, David A et al. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol 2017; 97(4): 489–92.
- Wetter DA, Davis MDP. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 pateints at Mayo Clinic, 2000–2007. J Am Acad Dermatol 2010; 62: 45–53.
- Stur K, Karlhofer FM, Stingl G. Soluble Fas ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J Invest Dermatol 2007; 127: 802–7.
- Ueta M, Sotozono C, Inatomi T et al. Association of Fas ligand gene polymorphism with Stevens Johnson syndrome. Br J Ophthalmol 2008; 92: 989–91.
- Posadas SJ, Padial A, Torres MJ et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109: 155–61.
- Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343–50.
References
- Huff JC, Weston WL, Tonnesen MG et al. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8: 763–75.
- Lamoreux MR, Sternbach MR, Hsu WT. Erythema multiforme. Am Fam Physician 2006; 74: 1883–8.
- Forman R, Koren G, Shear NH. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years’ experience. Drug Saf 2002; 25: 965–72.
- Von Hebra F. Atlas der Hautkrankheiten. Vienna: Kaiserliche Akademie der Wissenchafte, 1866.
- Weston WL, Morelli JG, Rogers M. Target lesions on the lips: childhood herpes simplex associated with erythema multiforme mimics Stevens–Johnson syndrome. J Am Acad Dermatol 1997; 37: 848–50.
- Lam NS, Yang YH, Wang LC et al. Clinical characteristics of childhood erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37: 366–70.
- Villiger RM, von Vigier RO, Ramelli GP et al. Precipitants in 42 cases of erythema multiforme. Eur J Pediatr 1999; 158: 929–32.
References
- Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343–50.
- Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019–24.
- Bastuji-Garin S, Rzany B, Stern SR et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92–6.
- Letko E, Papaliodis DN, Papaliodis GN et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of literature. Ann Allergy Asthma Immunol 2005; 94: 419–36.
- Van Batavia JP, Chu DI, Long CJ et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol 2017; 13(5): 490.
- Borchers AT, Lee JL, Naguwa SM et al. Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598–605.
- Koh MJA, Tay YK. An update on Stevens–Johnson syndrome and toxic epidermal necrolysis. Curr Opin Pediatr 2009; 21: 505–10.
- Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323–7.
- Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011; 128: 723–8.
- Olson D, Abbott J, Lin C et al. Characterization of children with recurrent episodes of Stevens Johnson syndrome. J Pediatr Infect Dis Soc 2017; 6: e140–e143.
References
- Forman R, Koren G, Shear NH. Erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years’ experience. Drug Saf 2002; 25: 965–72.
- Lam NS, Yang YH, Wang LC et al. Clinical characteristics of childhood erythema multiforme, Stevens–Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37: 366–70.
- Koh MJA, Tay YK. An update on Stevens–Johnson syndrome and toxic epidermal necrolysis. Curr Opin Pediatr 2009; 21: 505–10.
- Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007; 56: 181–200.
- Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens–Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323–7.
- Sotozono C, Ueta M, Koizumi N et al. Diagnosis and treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 2009; 116: 685–90.
- Hsu DY, Brieva J, Silverberg N. et al. Pediatric Stevens Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol 2017; 76: 811–17.
- Bastuji-Garin S, Fouchard N, Bertocchi et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149–53.
References
- Letko E, Papaliodis DN, Papaliodis GN et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of literature. Ann Allergy Asthma Immunol 2005; 94: 419–36.
- Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29: 269–76.
- Mayes T, Gottschlich M, Khoury J et al. Energy requirements of pediatric patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. Nutr Clin Pract 2008; 23: 547–50.
- Sotozono C, Ueta M, Koizumi N et al. Diagnosis and treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 2009; 116: 685–90.
- Tseng SCG. Acute management of Stevens–Johnson syndrome and toxic epidermal necrolysis to minimize ocular sequelae. Am J Ophthalmol 2009; 147: 949–51.
- Gueudry J, Roujeau JC, Binaghi M et al. Risk factors for the development of ocular complications of Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009; 145: 157–62.
- Majumdar S, Mockenhaupt M, Roujeau JC et al. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002; 4: CD001435.
- Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroS-CAR study. J Am Acad Dermatol 2008; 58: 33–40.
- Léauté-Labrèze C, Lamireau T, Chawki D et al. Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome. Arch Dis Child 2000; 83: 347–52.
- Kakourou T, Klontza D, Soteropolou F et al. Corticosteroid treatment of erythema multiforme major (Stevens–Johnson syndrome) in children. Eur J Pediatr 1997; 156: 90–3.
- Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139: 33–6.
- Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens–Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112: 1430–6.
- Faye O, Roujeau JC. Treatment of epidermal necrolysis with high dose immunoglobulins (IVIg): clinical experience to date. Drugs 2005; 65: 2085–90.
- Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 1995; 132: 267–70.
- Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1993; 5: 375–6.
- Weston WL, Morelli JG. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med 1997; 151: 1014–16.
- Borchers AT, Lee JL, Naguwa SM et al. Stevens–Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598–605.
- Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. J Cutan Med Surg 2018; 22: 514–515.
- St John J, Ratushny V, Liu K et al. Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Paediatr Dermatol 2017; 34: 540–546.
